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ABSTRACT  
          Erythropoietin (EPO) is a 30 kDa glycoprotein hormone 
which is important for red blood cells maturation. EPO consists of 
165 amino acids and possesses 3N-linked carbohydrate chains. 
Recombinant human erythropoietin (rHuEPO), such as epoetin-α 
and epoetin-β, have been used for many years to treat anemia in 
patients with chronic renal failure, systolic heart failure, HIV-
AIDS, or cancer. In vivo stability of rHuEPOs were low due to 
rapid metabolisms by galactosyl receptor of the hepatocytes. 
Previously, a novel erythropoiesis stimulating protein (NESP) 
called darbapoetin-α (DARB) which possesses two additional N-
linked glycosylation had been studied. It was observed that NESP 
showed better in vivo stability and biological activity compared to 
the unmodified form (containing only 3N-linked carbohydrate 
chains). Based on the above study, we attempted to synthesize 
recombinant human EPO (rHuEPO) by generating CHO-K1 cell 
lines expressing codon-optimized human epo open reading frame 
(ORF) in CHO-K1 cells. The ORF was modified to contain 5 N-
linked carbohydrate chains. The media obtained from CHO-K1 
cell culture was collected and diafiltrated with the use of 
tangential flow filtration. The rHuEPO protein containing 
polyhistidine tag was purified using affinity chromatography. An 
SDS/PAGE and Western blotting analyses confirmed that the 
purified protein was the modified rHuEPO. MTT based 
proliferation assay was conducted in TF-1 bone marrow cell line 
as a model. The result showed that the modified rHuEPO was 
able to enhance TF-1 cells proliferation.  
 




Erythropoietin (EPO) is one of protein 
hormones that commonly used in anemia 
caused by chronic renal failure (Lotscher, 2005; 
Pinevich and Petersen, 1991), systolic heart 
failure (Swedberg et al., 2013), HIV-AIDS, and 
cancer (Helena et al., 2006). It supports the 
production of red blood cells (Durocher and 
Butler, 2009; Goldwasser, 1975). Despite many 
efforts to synthesize this protein in many 
different expression systems, production of 
recombinant human EPO (rHuEPO) still relies 
on chinese hamster ovary (CHO) derived cells 
(Kiss et al., 2010). 
Endogenous human EPO EPO is a 30-
38kDa glycoprotein (exact molecular weight 
depends on the degree of glycosylation) in 
which 60% of the molecule composed of 165 
amino acid single polypeptide chain containing 
two disulphide bonds. The remaining 40% of 
the EPO mass consists of carbohydrate 
covalently attached at three N-linked sugar 
chain at Asn 24, 38 and 83, and one O-linked 
sugar chain at Ser126 (Skibeli et al., 2001; Egrie 
and Brown, 2001).  
Glycosylation of EPO does not 
correspond to its in vitro activity, but it 
significantly contributes to the enhancement of 
in vivo stability and activity (Egrie and Browne, 
2001). Functionally, glycosylation has been 
shown to influence a variety of critical 
biological processes at both the cellular and 
protein levels including its stability and long 
residence in body (Liu, 1992). Structurally, 
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glycosylation is highly complex due to the           
fact that there can be heterogeneity with 
respect to the site of glycan attachment 
(macroheterogeneity) and with respect to the 
glycan's structure (microheterogeneity) (Sears 
and Wong, 1998). With regard to this 
circumstances, the efforts to synthesize 
rHuEPO with higher in vivo stability and 
biological activity by modification of its 
glycosilation pattern was studied (Egrie and 
Browne, 2001). A novel erythropoiesis 
stimulating protein (NESP) called darbepoetin-
α was synthesized by changing of 5 amino acids 
(Ala30Asn, His32Thr, Pro887Val, Trp88Asn 
and Pro90Thr) in the invariant amino acids 
core (Egrie and Browne, 2001) allowing for 
additional oligosaccharide attachments at 
asparagine residues at position 30 and 88.             
The attachment of these oligosaccharides 
contributed to addition of molecular weight to 
approximately 37kDa. With more carbohydrate 
content, NESP shows higher in vivo stability 
and activity compared to those epoetins (Egrie 
and Browne, 2001; McDougall, 2002).  
In line with the previous study (Egrie 
and Browne, 2001), in this current study, we 
report the expression of hEPO in CHO-K1 
cells. Under the control of the CMV promoter, 
codon optimized of human epo gene containing 
five N-linked oligosaccharide chains was 
subcloned into PJ603 expression plasmid 
system. Protein rHuEPO secreted into the 
culture medium was purified using immobilized 
metal affinity chromatography (IMAC) and 
analyzed using Western blot.  In vitro analysis 
using bone marrow TF-1 cell line was also 
performed and discussed.   
 
MATERIALS AND METHODS 
Cell culture and reagents 
CHO-K1 cells were obtained from Prof. 
Masashi Kawaichi, Nara Institute of Science 
and Technology (NAIST), Japan. CHO-K1 
cells were cultured in Nutrient Mixture              
F-12 Ham (F12) media (Sigma N6658) 
supplemented with 10% of fetal bovine serum 
(FBS, Sigma), 100U of benzylpenicillin and 
100µg of streptomycin (Gibco, Invitrogen) in 
an incubator with addition of 5% CO2 at 37C. 
Cells were passaged every 2-3days. TF-1 cells 
(EC93022307-FO) were obtained from Saibou, 
Japan. TF-1 cells were grown in RPMI (Roswell 
Park Memorial Institute) 1640 media 
supplemented with 2mM of L-glutamine 
(Sigma), 10% of FBS (Gibco, Invitrogen), 100U 
of benzylpenicillin-100µg of streptomycin 
(Gibco, Invitrogen), and 5ng/mL granulocyte 
macrophage-colony stimulating factor (GM-
CSF, Invitrogen) in an incubator with addition 
of 5% CO2 at 37C. Cells were passaged every 
2-3day. Epoetin-α (3000IU/mL, Hemapo) 
from PT. Kalbe Farma (Indonesia) was used as 
a positive control. Antibiotics G418 (Geneticin) 
was obtained from Sigma.  
 
Expression of rHuEPOin CHO-K1 cells 
Codon optimized of human epo gene 
containing five N-linked carbohydrate chains 
was synthesized and subcloned into PJ603 
expression plasmid system by DNA 2.0          
(pJ-EPO). CHO-K1 cells were transfected  
with pJ-EPO recombinant plasmidby using 
Lipofectamin 2000(Invitrogen) according to 
manufacturer’s protocol. Stable expressing 
transformants were screened by using 1,000ng 
of G418. In addition, single clone cells were 
cultured in F12 medium supplemented           
with 10% of fetal bovine serum (FBS, Sigma), 
100U of benzylpenicillin 100µg of streptomycin 
(Gibco, Invitrogen) and 1.000ng of G418. 
 
Ultrafiltration and purification 
About 100mL of supernatant of culture 
medium was applied on diafiltration by using 
tangential flow filtration (Pall). Concentrated 
supernatant was then purified by using Ni 
Sepharose column (Histrap FF, GE 
Healthcare) and reconcentrated by using ultra 
centrifugal filter (Amicon, Merck) for Western 
blot. The recombinant protein rHuEPO 
resulted from the purification steps above was 
used for in vitro proliferation assay using TF-1 
cell line.   
 
Relative quantitation of rHuEPO 
Epoetin-α (45IU) and bovine serum 
albumin with various concentrations (25, 50, 
100, 150 and 200ng) were subjected into a 12% 
of SDS-PAGE (sodium dodecyl sulfate 
polyacrylamide gel electrophoresis) gel analysis. 
The gel was stained using CBB (coomassie 
brilliant blue) solution (Bio-Rad). Area under 
curve-based analysis was determined by using 
ImageJ   software.   Relative   concentration   of  
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epoetin-α was calculated by using BSA as 
standard.  Relative concentration of epoetin-α 
was used to determine our modified rHuEPO 
concentration. As much as 15µL of rHuEPO 
and epoetin-α (45IU) were analyzed in 12% of 
SDS-PAGE gel. The proteins then were the 
transfered into nitro cellulose membrane (GE 
Healthcare) by wet transfer method. The 
membrane was soaked in blocking solution 
containing 5% of skim milk. After washing 
with tris buffer saline containing 0.1% tween 
(TBS-T), the membrane was soaked in primary 
human polyclonal anti-EPO antibodies (1:1000, 
Calbiochem). Following the next washing step, 
the membrane was soaked in anti rabbit 
alkaline phosphatase linkeded antibody as the 
secondary antibody (3:10,000, Promega) and 
then visualized by nitroblue tetrazolium 
chloride-5-bromo-4-chloro-1H-indol-3-yl dihy-
drogen phosphate (NBT-BCIP, Promega). The 
same analysis using Image J was performed to 
obtain relative concentration of modified 
rHuEPO.  
 
MTT proliferation assay 
MTT (methylthiazol tetrazolium) 
proliferation assay of rHuEPO in TF-1 was 
done based on Hammerling et al. (1996).TF-1 
cells were cultured in RPMI 1640 media 
(Sigma) supplemented with 2mM L-glutamin 
(Sigma), 10% of FBS (Gibco), 4mM 100U 
benzyl penicillin- 100µg streptomycin (Gibco), 
5ng/mL GM-CSF (Invitrogen) in CO2 
incubator with 5% CO2 at 37C. One day 
before harvesting, the cells were washed with 
PBS and changed with medium without GM-
CSF. As much as 90µL of cells suspension were 
seeded in RPMI-1640 with serum and 
antibiotics respectively (without GM-CSF) into 
96-well microtiter plates at a density of 
2x105cells/mL. Cells were treated with 90µL of 
serial dilutions of modified rHuEPOand 
commercial epoetin-α. After 48h incubation, 
20µL of 6mg/mL of MTT solution was added 
to the cells and incubated for 4h. Formazan as 
a product of MTT convertion was dissolved by 
10% SDS in 0,01M HCl. The next day, optical 
density (OD) of each well was analyzed by 
microplate reader at 595nm. OD response was 
analyzed by substracting OD of treated well 
with OD of blank.   
 
RESULT AND DISCUSSION 
Detection of rHuEPO 
The PJ603 recombinant plasmid 
containing codon optimized of human epo gene 
with five N-linked oligosaccharide chains was 
transfected into CHO-K1 cells using 
Lipofectamine 2000, and G418 resistance 
colonies were selected. Individual clones were 
isolated and screened for the expression of 
hEPO   protein.  One  clone  expressing hEPO  
 
 
Figure 1. Detection of rHuEPO by Western blot. A) Supernatant of culture 
medium of CHO-K1 cells transfected with pJ-epo was purified by Ni-NTA 
agarose beads and concentrated by ultra centrifugal filter. rHuEPO, protein 
marker (M), and epoetin-α (H) were subjected to SDS PAGE and detected by 
Western blot. B) Relative area under curve of epoetin-α and rHuEPO bands were 
analyzed using ImageJ software. 
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was used for subsequent functional study.  The 
coding sequence of the therapeutically 
important human glycoprotein EPO was fused 
with a polyhistidine tag to enable easy, rapid 
purification. The expression of the human epo 
gene was placed under the control of CMV 
promoter. Following incubation in the presence 
of 5% CO2 at 37C for 2-3 days, the expressed 
rHuEPO protein was secreted into the 
medium. The media were collected by 
centrifugation at 6000rpm for 5min and the 
supernatant containing rHuEPO was collected 
while the cells were removed.  
Following purification, the sample was 
run on SDS/PAGE and detected with Western 
blot analysis using polyclonal anti human EPO 
antibody. Eventhough, the molecular mass of 
the expressed rHuEPO is about 37kDa, in this 
study, the signal of the  expressed protein was 
detected above 50kDa protein marker due to 
denaturation and glycosylation (Figure 1), while 
epoetin-α which was used as positive control 
detected below 50kDa protein marker. 
The remaining 40% of the native EPO 
mass consists of carbohydrate covalently 
attached at three N-glycans sugar chains at Asn 
24, 38 and 83, and one O-linkeded sugar chain 
at Ser126 (Browne et al., 1986; Davis et al., 
1987; Miyake et al., 1977). Since the consensus 
sequences for N-linked glycans was known 
(Asn-X-Ser/Thr where X is any amino acid 
except proline), we speculate that the increase 
in size of this molecular mass is attributed to 
the attachment of two additional oligo-
saccharides at asparagine residues positions 30 
and 88. The increase of this molecular mass 
increase the average carbohydrate content of 
the molecule from 38% to 50% (data not 
shown) and the maximum number of sialic 
acids from 14 to 22 (Egrie and Browne, 2001). 
 
Dertermination of rHuEPO concentration 
Since we were not able to detect the 
presence of rHuEPO protein in CBB staining, 
we modified this detection using combination 
of Western blot and CBB staining. As much as 
45 IU of epoetin alpha was quantified using 
BSA at concentration of 50, 100, 150 and 
200ng as protein control in SDS/PAGE               
gel (Figure 2). Using ImageJ software, it was 
found that epoetin-α in Hemapo was about 
2.9ng/µL. By knowing weight quantity of 
epoetin-α, we then quantify the concentration 
of our rHuEPO sample by running the 10 x 
concentrated sample in SDS/PAGE using 
epoetin-α as protein control. Calculated using 
the software, it is predicted that the 
concentration of rHuEPO was approximately 
0.09ng/µL. 
 
Analysis of rHuEPO in vitro proliferation 
activity 
Following characterization of hyper-
glycosylated rHuEPO, in vitro biological activity 
was performed. For this purpose the human 
erythroleukemia cell line TF-1 was employed 
for determination of proliferative stimulation 
 
 
Figure 2. Detection of rHuEPO by CBB staining. A. H = epoetin-α(45 IU), M = 
protein marker, 1-5 = bovine serum albumin (BSA) 25, 50, 100, 150 and 200 ng 
respectively; B. Relative area under curve of epoetin-α and BSA bands were 
analyzed by ImageJ software. 
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induced by rHuEPO protein. MTT 
proliferation assay of epoetin-α on TF-1 cells 
indicated that epoetin-α at concentration below 
1 IU enhanced proliferation of TF-1 cells 
(Table I). However, when concentration of 
epoetin-α at more than 1 IU the proliferation of 
TF-1 cells decreased (data not shown).  
Purified rHuEPO sample that had been 
synthesized in CHO-K1 cells showed 
enhancement of TF-1 proliferation. Moreover, 
activity of our rHuEPO was comparable to 
epoetin-α (Table II). Considering the 
concentration of rHuEPO was about 
0.09ng/µL, thus, the activity of 0.18ng of 
expressed rHuEPO was similar to 2ng of 
epoetin-α (Table I and II). As additional 
information, both epoetin-α in Hemapo and 
our modified rHuEPO sample contain small 
amount of albumin as stabilizer.  
The development of hEPO for the 
correction of anemia related diseases is a 
dramatic example of how much hEPO research 
has been progressing. Initially, it took 20 years 
to purify a few milligrams of erythropoietin 
from over 2.5L of urine from patients with 
aplastic anemia (Miyake et al., 1977). The first 
replacement therapy for anemia patient with 
chronic renal failure was to administer native 
erythropoietin from human urinary. The 
activity of human urinary EPO is 70,000 
IU/mg (Jelkmann, 2006). This massive effort 
provided the basis for the cloning of the human 
erythropoietin gene in 1985 and the possibility 
for large-scale production (Jacobs, et al., 1985). 
Since then, the use of recombinant hEPO is 
widely used for treatment of anemia in patients 
suffer from anemia related diseases (Lotscher, 
2005; Pinevich and Petersen, 1991; Swedberg et 
al., 2013). This epoetin-α shows higher in vivo 
activity than that of urinary EPO, about 
200.000IU/mg, probably due to more complete 
glycosylation (Jelkmann, 2006). In line with 
this, currently, one of the most significant 
progresses in EPO research is the development 
of darbapoietin, an EPO molecule with 
additional glycosylations resulting in a 
significantly longer half-life and a reduced 
dosing frequency.  
Related to the previous study (Egrie and 
Browne, 2001), in this study, we expressed 
modified rHuEPO with 2 addition of N-linked 
glycosylations in adherent CHO-K1 cells base. 
The expressed protein was detected by Western 
blotting above 50kDa which was higher than 
that of epoetin-α. Molecular weight of our 
modified rHuEPO supposed to be similar to 
NESP, about 37kDa. Various studies have 
reported that expression of heterologous 
Table I. In vitro activity of epoetin-α on proliferation of TF-1 cells. 
 
IU/well ng/well* OD + SD** 
0.1 0.1 0.037+ 0.002 
0.2 0.2 0.046 + 0.006 
0.4 0.3 0.051 + 0.002 
0.8 0.8 0.059 + 0.012 
 
* Calculated based on epoietin-α activity (about 1 IU/ng). 
** OD was analyzed by substracting the blank well OD from the treated ones.     
 
Table II. In vitro activity of modified rHuEPO on proliferation of TF-1 cells. 
 
µL/well ng/well* OD + SD** 
0.33 0.03 0.035 + 0.002 
0.67 0.06 0.048 + 0.005 
1.33 0.12 0.036 + 0.002 
2 0.18 0.046 + 0.002 
2.67 0.24 0.067 +0.002 
 
* Calculated based on rhEPO concentration (about 0.09 ng/µL). 
** OD was analyzed by substracting the blank well OD from the treated ones.     
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glycosylated recombinant protein may result in 
a greater molecular mass than it should be. This 
may be caused by the degree in the 
glycosylation itself or denaturation. This result 
was similar to that had been reported by Gross 
and Lodish (2006). The difference of molecular 
weight of our modified rHuEPO and epoetin-α 
was about 7.5kDa. This additional molecular 
weight might be contributed from two 
additional N-linked carbohydrate chains (about 
6.6kDa) and  6xhistag sequence (about 1kDa) 
(Egrie and Bowne, 2001; Terpe, 2003).  
To verify that glycosylation was indeed 
contributed to an increase of molecular weight, 
we use enzymatic removal of the glycans 
moiety of the expressed protein with PNGase 
F.  PNGase F has been utilized extensively for 
demonstrating shifts in SDS/PAGE mobilities 
as an indication of N-glycosylation. Digestion 
with PNGase F resulted in a band with a 
molecular mass approximately corresponds to 
the molecular mass of the polypeptide 
backbone and both our modified rHuEPO and 
epoetin-α appeared in the same size which is 
about 20kDa. Thus, it is very likely that our 
modified rHuEPO was the hyperglycosylated 
EPO with 2 addition of carbohydrate chains 
(Santoso et al., 2012).  
Proliferation assay of our modified 
rHuEPO and epoetin-α were done in human 
erythroleukemia TF-1 cells. It has been 
reported that in vitro proliferation assay of EPO 
in TF-1 cells show high accuracy (Hammerling 
et al., 1996). Treatment of TF-1 cells with EPO 
in 24h down-regulates the EpoR and reach a 
peak in 6h. Moreover, in TF-1 cells, EPO  only 
stimulates proliferation for short period of time 
(Kitamura et al., 1989). In this study, the result 
indicated that our modified rHuEPO showed 
comparable proliferative activity with that oh 
epoetin-α. Epoetin-α showed enhancement of 
TF-1 cells proliferation at concentration below 
1IU and its activity declines at concentration 
more than 1IU. However, concentration of 
epoetin-α used in this study was remained 
higher than its physiologic concentration range 
(Urabe et al., 1987).  
It has been shown that the addition of 
carbohydrate is required for secretion, stability, 
delay clearance and biosynthesis (Sola et al., 
2010). However, the carbohydrate is not 
essential for the biological activity of EPO          
in vitro, indicating that only the polypeptide is 
involved in binding to the EPO receptor. On 
the other hand, proper glycosilation of EPO is 
absolutely critical in in vivo condition (Egrie and 
Browne, 2001). Since in our current experiment 
the functional analysis performed was in vitro 
study, thus the addition of 2-oligosaccharide 
attachments (at position 30 and 88) has no 
effect.  
Previous study reported that that two 
additional N-linked glycosylations of NESP 
causes its molecule to be more bulky. Thus, it 
makes NESP to have lower in vitro activity than 
that of epoetin-α (Egrie and Browne, 2001).  
However, excessive amount of NESP shows 
similar in vitro activity with that of epoetin-α 
(Elliot et al., 2004). Affinity of NESP to its 
receptor (EpoR) is lower than that of epoetin-
α, but activity of NESP in vivo is higher than 
epoetin-α. With lower binding affinity to EpoR, 
NESP is also released slower (Gross and 
Lodish, 2006). Moreover, with more glycosyl 
groups of NESP, the enzymatic digestion rate 
of NESP by galactosyl receptor in liver is lower 
than epoetin-α. Altogether, the resultant in vivo 
activity of NESP is greater than that of epoetin-
α; and modification of rHuEPO is very 




In this study we expressed modified 
rHuEPO in CHO-K1 cells. The result showed 
that the modified rHuEPO enhanced TF-1 
cells proliferation. In vitro proliferation assay 
indicated comparable values between our 
rHuEPO and epoetin-α.  
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